Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 MEC-V DEMONSTRATES MEDIAN OS OF 21.5 MONTHS IN PATIENTS WITH TREATMENT-REFRACTORY LEIOMYOSARCOMA, LIPOSARCOMA, AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA COMPARED WITH APPROXIMATELY 12 MONTHS WITH APPROVED AGENTS

BIOATLA'S MECBOTAMAB VEDOTIN (MEC-V), AN AXL-TARGETING ADC, DEMONSTRATES A MEDIAN OVERALL SURVIVAL (OS) OF 21.5 MONTHS IN SUBTYPES OF REFRACTORY SOFT TISSUE SARCOMAS

SAN DIEGO, NOV. 05, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT IT PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, NOVEMBER 13, 2025 AT 4:30 P.M. ET TO DISCUSS ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND PROVIDE BUSINESS HIGHLIGHTS.

BIOATLA TO ANNOUNCE THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS HIGHLIGHTS ON NOVEMBER 13, 2025

SAN DIEGO, OCT. 23, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED PRESENTATION OF A POSTER ENTITLED TARGETING HPV E6/E7 UPREGULATION OF THE TRANSMEMBRANE RECEPTOR TYROSINE KINASE ROR2 WITH THE ADC OZURIFTAMAB VEDOTIN IN PATIENTS WITH ADVANCED HPV+ OROPHARYNGEAL SQUAMOUS CELL CARCINOMA WHICH DETAILS CLINICAL DATA FROM ITS INVESTIGATIONAL ANTIBODY-DRUG CONJUGATE (ADC), OZURIFTAMAB VEDOTIN (OZ-V), AT THE INTERNATIONAL PAPILLOMAVIRUS SOCIETY (IPVS) CONFERENCE, TAKING PLACE OCTOBER 2326, 2025, IN BANGKOK, THAILAND.

BIOATLA PRESENTS COMPELLING MECHANISTIC RATIONALE FOR TARGETING ROR2 WITH OZURIFTAMAB VEDOTIN (OZ-V) IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) AT THE ANNUAL CONFERENCE OF THE INTERNATIONAL PAPILLOMAVIRUS SOCIETY

ADVERSE EVENTS (AES) GENERALLY TRANSIENT AND READILY MANAGEABLE; ONLY 2 CASES OF CYTOKINE RELEASE SYNDROME (CRS) PROLONGED TUMOR CONTROL WITH INCREASING DOSES OF BA3182; CONFIRMED PARTIAL RESPONSE (CPR) AT 0.6 MG IN A PATIENT WITH INTRAHEPATIC CHOLANGIOCARCINOMA WITHOUT PROGRESSION FOR >6 MONTHS MAXIMALLY TOLERATED DOSE NOT YET DEFINED; DOSE ESCALATION CONTINUES; CURRENTLY TESTING 1.8 MG DOSE LEVEL SAN DIEGO, OCT. 20, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED PRELIMINARY CLINICAL DATA FROM A PHASE 1 STUDY OF BA3182 DURING A POSTER PRESENTATION TITLED PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF BA3182, A DUAL-CONDITIONALLY BINDING BIOLOGIC (CAB) EPCAM X CD3 BISPECIFIC T-CELL ENGAGER IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025, HELD IN BERLIN, GERMANY. THE POSTER WAS FEATURED IN THE INVESTIGATIONAL IMMUNOTHERAPY SESSION ON SUNDAY, OCTOBER 19.

BIOATLA PRESENTS PROMISING INTERIM DATA FROM ITS PHASE 1 TRIAL WITH BA3182 IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT ESMO 2025

SAN DIEGO, OCT. 03, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS USING ITS PROPRIETARY CAB PLATFORM FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT CLINICAL DATA FOR ITS INVESTIGATIONAL AXL-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), MECBOTAMAB VEDOTIN (BA3011), WILL BE PRESENTED AT THE UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2025 ANNUAL MEETING TO BE HELD AT NATIONAL HARBOR, MD FROM NOVEMBER 5-9, 2025.

BIOATLA TO PRESENT CLINICAL DATA FOR MECBOTAMAB VEDOTIN (BA3011) IN SOFT TISSUE SARCOMA AT SITC 2025

FDA ALIGNMENT ON PHASE 3 OZURIFTAMAB VEDOTIN (OZ-V) TRIAL DESIGN, INCLUDING DOSING REGIMEN AND ENDPOINTS TO SUPPORT POTENTIAL ACCELERATED APPROVAL COMPANY CONTINUES PREPARATIONS FOR ENABLING INITIATION OF THE PHASE 3 STUDY WITH THE GOAL OF ADVANCING THE STUDY WITH A STRATEGIC PARTNER EARLY NEXT YEAR COMPANY MAINTAINS PREVIOUS GUIDANCE FOR COMPLETION OF A STRATEGIC PARTNERSHIP WITH ONE OF OUR ADVANCED CLINICAL ASSETS THIS YEAR SAN DIEGO, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS USING ITS PROPRIETARY CAB PLATFORM FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED OUTCOMES FROM ITS TYPE B MEETING WITH THEUNITED STATES FOOD AND DRUG ADMINISTRATION(FDA).

BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR OZURIFTAMAB VEDOTIN IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) FOLLOWING PRODUCTIVE TYPE B (END OF PHASE 2) MEETING WITH FDA

CAB-EPCAM X CAB-CD3 BISPECIFIC T-CELL ENGAGER (TCE) (BA3182) PHASE 1 DOSE-ESCALATION STUDY ONGOING, CURRENTLY DOSING 1.2 MG COHORT; PHASE 1 DATA READOUT

BIOATLA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

SAN DIEGO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF

BIOATLA TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTSAND PROVIDE BUSINESS HIGHLIGHTS ON AUGUST 7, 2025

SAN DIEGO, JULY 17, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY OR BIOATLA), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED AN ORAL PRESENTATION AT THE UPCOMING 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) TAT ASIA MEETING TO BE HELD IN HONG KONG SAR, CHINA FROM JULY 1820, 2025. ORAL PRESENTATION DETAILS:    TITLE:  FIRST-IN-HUMAN PHASE I STUDY OF A DUAL-CONDITIONALLY ACTIVE BIOLOGIC (CAB) EPCAM X CD3 BISPECIFIC T-CELL ENGAGER (TCE), BA3182, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AUTHORS:  JENNIFER B.

BIOATLA ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) TAT ASIA MEETING

ADVERSE EVENTS WERE GENERALLY LOW-GRADE, TRANSIENT, AND READILY MANAGEABLE ACHIEVED PRELIMINARY EVIDENCE OF PROLONGED TUMOR CONTROL AND TUMOR REDUCTIONS

BIOATLA PRESENTS DATA FROM ONGOING DOSE ESCALATION OF BA3182, DUAL-CONDITIONALLY BINDING EPCAM X CD3 BISPECIFIC T-CELL ENGAGER, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) GASTROINTESTINAL CANCERS CONGRESS

45% OVERALL RESPONSE RATE (ORR) AND A 100% DISEASE CONTROL RATE (DCR) IN HPV+ OPSCC PATIENTS TREATED WITH A MEDIAN OF 3 PRIOR LINES OF THERAPY MARKED UNMET NEED EXISTS IN 2L+ HPV+ OPSCC PATIENTS; STANDARD OF CARE AGENTS (METHOTREXATE, DOCETAXEL, OR CETUXIMAB) REPORT AN ORR OF 3.4% PLAN TO FINALIZE PHASE 3 TRIAL DESIGN IN 2L+ HPV+ OPSCC WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SAN DIEGO, JUNE 02, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED DATA IN A POSTER TITLED, PHASE 2 TRIAL OF OZURIFTAMAB VEDOTIN (OZ-V), A CONDITIONALLY BINDING CAB-ROR2-ADC, IN PATIENTS WITH HEAVILY PRETREATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. THE POSTER WILL BE PRESENTED TODAY AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING AT THE MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

BIOATLA PRESENTS PHASE 2 OZURIFTAMAB VEDOTIN (OZ-V) CLINICAL TRIAL DATA DEMONSTRATING COMPELLING ANTITUMOR ACTIVITY IN HPV-ASSOCIATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (HPV+ OPSCC) AT THE 1.8 MG/KG Q2W DOSING REGIMEN

BioAtla, Inc.

BCAB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BioAtla, Inc.

BCAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BCAB